Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-15
2006-08-15
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S018000
Reexamination Certificate
active
07091211
ABSTRACT:
Cyclopentyl compounds of Formula (I) are modulators of chemokine receptor activity:wherein D, G, R2, R3and R8in Formula (I) are defined herein. The compounds, and pharmaceutically acceptable salts and individual diastereomers thereof, are useful in the treatment and prevention of HIV infection, in delaying the onset of AIDS, and in the treatment of AIDS. The compounds are also useful for treating other diseases and conditions mediated by chemokine receptors.
REFERENCES:
patent: 5468469 (1995-11-01), Aszalos et al.
patent: 5607936 (1997-03-01), Chiang et al.
patent: 5869496 (1999-02-01), Hale et al.
patent: 5962462 (1999-10-01), Mills et al.
patent: 6013644 (2000-01-01), Mills et al.
patent: 6358979 (2002-03-01), Finke et al.
patent: 6432981 (2002-08-01), Finke et al.
patent: 6472410 (2002-10-01), Finke et al.
patent: 6500844 (2002-12-01), Finke et al.
patent: 6506777 (2003-01-01), Finke et al.
patent: 6538002 (2003-03-01), Finke et al.
patent: 6593346 (2003-07-01), Finke et al.
patent: WO 94/17045 (1994-08-01), None
patent: WO 94/29309 (1994-12-01), None
patent: WO 96/10568 (1996-04-01), None
patent: WO 01/78707 (2001-10-01), None
Devalaraj et al Multiple Chemotactic factors : fine control or redundancy , 1999.
Dean et al Genetic Restrictions of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene 1996.
Fauci Anthony et al Acquired Immunodeficiency Syndrome—1984.
Choe et al The B- Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates-1996.
Murphy, P., et al., “The Molecular Biology of Leukocyte Chemoattractant Receptors”, Annual Review of Immunology, vol. 12, No. 1, pp. 593-633 (1994).
Schall, T.J. “Biology of the RANTES/SIS Cytokine Family”, Cytokine, vol. 3, No. 3, pp. 165-183 (1991).
Deng, H., et al., “Identification of a Major Co-receptor for Primary Isolates of HIV-1”, Nature, vol. 381, pp. 661-666 (1996).
Horuk, R., “Molecular Properties of the Chemokine Receptor Family”, Trends in Pharmaceutical Science, vol. 15, pp. 159-165 (1994).
Ben-Baruch, A., et al., “Monocyte Chemotactic Protein-3 (MCP3) Interacts with Multiple Leukocyte Receptors”, Journal of Biological Chemistry, vol. 270, No. 38, pp. 22123-22128 (1995).
Neote, K., et al., “Molecular Cloning, Functional Expression, and Signaling Chracteristics of a C-C Chemokine Receptor”, Cell, vol. 72, pp. 145-425 (1993).
Combadiere, C., et al., “Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor”, Journal of Biological Chemistry, vol. 270, No. 27, pp. 16491-16494 (1995).
Power, C.A., et al., “Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor cDNA from a Human Basophilic Cell Line”, Journal of Biological Chemistry, vol. 270, No. 33, pp. 19495-19500 (1995).
Samson, M., et al., “Molecular Cloning and Functional Expression of a New Human CC-Chemokine Receptor Gene”, vol. 35, pp. 3362-3367 (1996).
Chaudhuri, A., et al., “Expression of the Duffy Antigen in K562 Cells”, Journal of Biological Chemistry, vol. 269, No. 11, pp. 7835-7838 (1994).
Kita, H., et al., “Chemokines Active on Eosiniphils: Potential Roles in Allergic Inflammation”, J. Exp. Med., vol. 183, pp. 2421-2126 (1996).
Smith, D.H., et al., “Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen”, vol. 238, pp. 1704-1707 (1987).
Levy, J.A., “Infection by Human Immunodeficiency Virus—CD4 is Not Enough”, N. Engl. J. Med., vol. 335, No. 20, pp. 1528-1530 (1996).
Dragic, T., et al., “HIV-1 Entry into CD4+ Cells is Mediated by the Chemokine Receptor CC-CKR-5”, Nature, vol. 381, pp. 667-673 (1996).
Wu, L., et al., “CD4-induced Interaction of Primary HIV-1 gp120 Glycoproteins with the Chemokine Receptor CCR-5”, Nature, vol. 384, pp. 179-183 (1996).
Trkola, A., et al., “CD4-dependent, Antibody-sensitive, Interactions Between HIV-1 and its Co-receptor CCR-5”, Nature, vol. 384, pp. 184-187 (1996).
Samson, M., et al., “Resistance to HIV-1 Infection in Caucasian Individuals Bearing Mutant Alleges of the CCR-5 Chemokine Receptor Gene”, Nature, vol. 382, pp. 722-725 (1996).
Hill, M.C., et al., “Natural Resistance to HIV?”, Nature, vol. 382, pp. 668-669 (1996).
Huang, Y., et al., “The Role of a Mutant CCR5 Allele in HIV-1 Transmission and Disease Progression”, Nature Medicine, vol. 2, No. 11, pp. 1240-1243 (1996).
Zhang, L., et al., “HIV-1 subtype and Seond-receptor Use”, Nature, vol. 383, p. 768 (1996).
Finke Paul E.
Loebach Jennifer L.
Mills Sander G.
Parker Kerry A.
Plummer Christopher W.
Camara Valerie J.
Desai Rita
Merck & Co. , Inc.
Walton Kenneth R.
LandOfFree
Cyclopentyl modulators of chemokine receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopentyl modulators of chemokine receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopentyl modulators of chemokine receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682791